Biotech and Pharmaceutical Stocks in the S&P 500 Index
Comprehensive tracking of the S&P 500 healthcare giants driving medical innovation, gene editing, and oncology breakthroughs in 2026.
The Biotech and Pharmaceutical Stocks in the S&P 500 Index represent the most influential healthcare entities in the global financial market. These companies are all part of the S&P 500 Healthcare Sector, which currently comprises over 12% of the total index weighting. As of early 2026, the sector has seen a massive resurgence driven by AI-accelerated drug discovery and high-profile M&A activity. While smaller biotechs offer explosive growth, the S&P 500 constituents listed below provide a balance of clinical-stage innovation and established revenue streams through blockbuster therapeutics.
Market Overview
Healthcare Sector Takeaways 2026
M&A Acceleration
Consolidation remains a primary driver, with large-cap pharmaceutical firms acquiring niche biotech pipelines to offset upcoming patent cliffs.
AI Therapy Integration
AI-driven drug discovery has reduced clinical trial timelines by an average of 18 months, significantly lowering the cost of innovation for index leaders.
Stable Dividend Yields
Large-cap pharma stocks like Amgen and Merck continue to offer attractive yields (2.5% - 4.0%), providing a defensive buffer during market volatility.
Oncology & Immunology
These sub-sectors represent over 60% of current clinical pipelines within the S&P 500 healthcare constituents, attracting major institutional capital.
Performance Metrics
S&P 500 Healthcare Leaders Table
| Company | Ticker | Market Cap | YTD Return | Dividend Yield | Focus Areas |
|---|---|---|---|---|---|
| Amgen Inc. | AMGN | $173B | +18.2% | ~3.0% | Oncology, Cardiovascular |
| Gilead Sciences | GILD | $150B | +31.4% | ~3.8% | HIV, Oncology |
| Vertex Pharma | VRTX | $113B | -5.1% | N/A | Cystic Fibrosis |
| AbbVie Inc. | ABBV | $312B | +12.4% | ~4.0% | Immunology, Neuroscience |
| Merck & Co. | MRK | $325B | +14.8% | ~2.5% | Vaccines, Animal Health |
Directory
Biotech and Pharmaceutical S&P 500 Components
The companies on this list are biotech and pharmaceutical companies in the S&P 500 index. These companies are all part of the S&P 500 Healthcare Sector.
Additional biotech and pharmaceutical companies can be located in the following sections:
Select the company’s link to access charts, news links and company website and social media information.
- Abbott Laboratories (ABT) (Nutritional products; medical devices, diagnostics, pharmaceuticals: generic pharmaceuticals gastroenterology products, therapeutic nutrition for dialysis patients, women’s health products, cardiovascular and metabolic, pain and nervous system, respiratory drugs, vaccines; vascular products)
- AbbVie Inc. (ABBV) (Biopharmaceutical company: immunology, kidney disease, liver disease, neuroscience, oncology, women’s health)
- Alexion Pharmaceuticals, Inc. (ALXN) (Biopharmaceutical company: nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, hypophosphatasia, Lysosomal Acid Lipase Deficiency)
- Allergan plc (AGN) (Generics, biosimilars, dermatology and aesthetics, central nervous system, eye care, women’s health and urology, GI and cystic fibrosis, cardiovascular and infectious disease)
- Amgen Inc. (AMGN) (Therapeutics: cardiovascular, inflammation, oncology, biosimilars)
- Biogen Inc. (BIIB) (Biopharmaceutical company: therapies for immunology, hematology, multiple sclerosis, neurology)
- Bristol-Myers Squibb Company (BMY) (Biopharmaceutical company: cancer, cardiovascular disease, hepatitis B and hepatitis C, HIV/AIDS, rheumatoid arthritis)
- Celgene Corporation (CELG) (Biopharmaceutical company: cancer and immune-inflammatory related diseases)
- Eli Lilly and Company (LLY) (Animal health, cardiovascular, critical care, diabetes, men’s health, musculoskeletal, neuroscience, oncology)
- Gilead Sciences, Inc. (GILD) (Biopharmaceutical company: cardiovascular, human immunodeficiency virus (HIV), liver diseases, oncology and inflammation, respiratory)
- Johnson & Johnson (JNJ) (Consumer health products: baby care, skin care, oral care, wound care and women’s health care; Medical devices: diabetes care, diagnostics, orthopaedics, neurological disease, vision care, infection prevention, cardiovascular disease and aesthetics; Pharmaceutical: cardiovascular and metabolic diseases, immunology, infectious diseases, neuroscience, oncology)
- Incyte Corporation (INCY) (Biopharmaceutical company: small molecule drugs; oncology and inflammation)
- Merck & Company, Inc. (MRK) (Pharmaceuticals: cardiovascular, diabetes, general medicine, immunology, infectious diseases, oncology, respiratory, women’s health; Vaccines, Animal Health Products)
- Mylan Inc. (MYL) (Generic, branded generic and specialty pharmaceuticals)
- Nektar Therapeutics (NKTR) (Biopharmaceutical company: anti-infective, anti-viral, immunology, oncology, pain)
- Perrigo Company (PRGO) (Ireland: generic over-the-counter, prescription pharmaceuticals, nutritional products, active pharmaceutical ingredients)
- Pfizer, Inc. (PFE) (Consumer healthcare products; vaccines; oncology; examples of medicines include treatments for the following areas: cardiovascular/metabolic, inflammation, neuroscience, pain, rare diseases, women’s/men’s health)
- Regeneron Pharmaceuticals, Inc. (REGN) (Biopharmaceutical company: Antibody technologies; cardiovascular, diabetes, eye diseases, infectious diseases, inflammation, oncology, pain)
- Vertex Pharmaceuticals Incorporated (VRTX) (Cystic fibrosis; additional ongoing research programs aimed at other serious and life-threatening diseases)
- Zoetis Inc. (ZTS) (Animal health medicines and vaccines, diagnostic products and genetic tests)
Risk Analysis
Investment Risks & Opportunities
Clinical Trial Failure
Biotech stocks often experience extreme volatility following Phase II or III trial data. Even large-cap firms can see market cap swings based on pipeline updates.
The Patent Cliff
When a drug's patent expires, generic competition significantly reduces revenue. Index components must constantly innovate or acquire to maintain growth.
Policy & Pricing
Changes in healthcare policy and drug pricing legislation remain a major macro headwind for the pharmaceutical sub-industry.
Effective 2026, diversification within the S&P 500 Healthcare sector is considered a primary strategy for mitigating clinical-stage asset risks.
Questions & Answers